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During the past 2 decades there has been a progressive 
revision of the role of digitalis in the management of con&s- 
tive heart failure. The availability of alternative drugs has 
reduced the dependence of the Gnician on digitalis as the 
principal approach to management of this disorder and has 
modified the approach todigitalis therapy in those patients in 
whom a valid indication for the drug continues to exist. 
What is the rationale for the we of digoxin in the 
management of patients with chronic congestive heart fait- 
we? We should acknowledge that digoxin is not necessarily 
the drug oftint choice after diuretics in o/l patients with this 
syndrome. Most therapeutic entities pass from a phase of term dig&t therapy and were repeated after the drug was 
initial (and often unwarranted) enthusiasm that-with recog- discontinued for 6 weeks. The withdrawal of digitalis was 
nition ofdrug failures and unwanted side effects-is followed accompanied by hemodynamic deterioration in all nine pa- 
by a phase of (often unwarranted) disillusionment and pes- tients, as reflecled by a decrease in left ventricular stroke 
simism. After years of use, as subsets of patients are defined work index and an increase in pulmonary capillary wedge 
and dosing regimens are refined. a balanced consensus pressure at rest and during exercise; this deterioration was 
emerges regarding the risks and benefits of a specific thera- reversed after reinstitution of digitalis therapy. Symptoms of 
peutic approach in various subsets of patients. After 200 heart failure worsened after the withdrawal of digitalis in five 
years we are reaching this third phase in the case of the of the nine patients. most notably in those with the most 
cardiac glycosides. Our challenge, therefore, is to define advanced congestive heart failure. These long-term hemo- 
which subsets of patients with chronic congestive heart dynamic benefits of digitalis at rest were subsequently con- 
failure have a favorable balance between risk and benefit firmed in elderly patients by Ware et al. (9) and during 
when treated with digitalis. exercise by Murray et al. (IO!. These beneficial effects of 
Risks of digitalis therapy. Although digitalis may produce digitalis on cardiac perfomwtce do not depend on the 
cardiac and noncardiac side effects, roost of these adverse specific cause of left ventricular systolic dysfunction, hut 
reactions are reversible and do not alter the long-term appear lo he similar in patients with ischemic, valvular or 
morbidity and morlalily of patients with congestive heart idiopathic cardiomyopathic disease (II). 
failure. Among more than 4,300 digitalis-treated patients Clinical beneSts of digitalls Iherapy. Are titese hemodp 
monitored in Boston area hospitals between 1966 and 197.5 namic benefits translated into the relief of symptoms and an 
(0, adverse rexlions attributable lo digitalis occurred in improvement in exercise tolerance? Unfortunately, most 
12% of patients, but were believed to have possibly contrib- studies that have evaluated the efficacy ofdigitalis have been 
ured to death in only 2 individuals. both of whom had severe seriously flawed and convey little useful information on 
congestive heart failure and chronic obstructive pulmonary which clinical decisions can he based. In their review of all 
disease. Thus, only about 0.05% of patients receiving digox- 16 studies published between 1960 lo 1982 that evaluated the 
in were reported lo have had a fatal episode of toxicity eklicacy of digitalis in patients with chmnic heart failure and 
possibly related to digitalis. It is important to note that this nonttal sinus rhythm, Mttlrow et al. (12) concluded that only 
record of safety was compiled before the widespread mea- two studies were both double-blinded and placeho- 
surernerd of serum digoxin levels. before digoxin-specific controlled and, hence. could provide unbiased infomtation. 
Fab fragments were available for the treatment of advanced The other studies failed to define clearly their selection of 
and potentially life-threatening drug toxicity and at the time patients, confimt the diagnosis of heart failure or employ 
when it was common clinical practice lo increase the dose of adequate cotttrols. 
digitalis to maximal tolerated doses when signs and symp- In rllefrsr placebo-conrrolled, double-blind trial of digox- 
lams of congestive heart failure persisted. Thus, although in in heart foilwe, Dobbs et al. (13). utilizing a crossover 
digitalis toxicity is not rare (2), fatal outcomes during routine design, observed that I6 of 46 patients with stable chmnic 
clinical use of the drug appear to be quite uncommon. The heart failure exhibited symptomatic deterioration when dig- 
possibility lhat digitalis may increase the risk of death in oxin was replaced by a placebo. However, of the 46 patients 
patients recovering from an acute myocardial infarction has in this study, IO had car pulmonale and 13 had atrial 
been vigorously debated (3-6); if any added risk from arrhythmias: unfortunately, the investigators never made 
digitalis can he validly identified in these studies. the effect clear how many of the 16 patients who required digitalis had 
appears to be sufficiently small that a very large prospective atrial fibrillation on entry into the trial. The study also failed 
randomized study would be required to detect such a modest lo describe how other therapeutic modalities for heart failure 
adverse effect on mortality (6.7). (diuretics, for example) were controlled during the crossover 
Hamodynamic benefits of digitalis therapy. Does digitalis from digoxin to placebo. 
therapy produce suntained hemodynamic effects in patients The Jirsr rigomrts, double-blinded, placebo-controlled. 
with chruoic heart failure” Nearly every study that has randomized @ial of digits/is in mnbrdarory palima with 
evaluated this question using precise hemodynamic mea- rinru rhyrhm ws condr,cred by Lee er al. (14). For purposes 
surements has axtcluded that the well established short- of this crossover study. these investigators developed a 
term effects of digitalis on cardiac perfomnnce persist heart failure score based on both the signs and the symptoms 
during long_term treatment with the drug. Arnold et al. (8) of hearI failure. All patients continued lo receive diuretics in 
evaluated the efficacy of digoxin in nine middle-aged patients doses that were considered optimal by the physician caring 
with severe congestive heart failure, all of whom had ao for the patient. The principal resttI1s of this study are shown 
enlarged left ventricle secondary to either irchemic heart in Figure I, which is redrawn from the original publication. 
disease or dilated cardiomyopathy. Invasive hemodynamic The condition of the majority gf the patients who entered 
measurements were initially carried out during stable long- this study improved during treatment with dig&n (shown 
as part of a comparative study of digoxin and mihinonc in 
these same patients. Two hundred thirty patients with con- 
tinued symptoms of heart failure despite digoxin and diuret- 
ics were randomly assigned to continued therapy with dig+ 
xin. the withdrawal of digoxin, the addition of mihinone or 
the substitution of mihinone for digoxin. Must of these 
patients were in New York Heart Association INYHAI 
functional class III. After 3 months of therapy, patients who 
continued to receive digoxin were better symptomatically 
and showed a significantly longer exercise tolerance than did 
patients who had been withdrawn from treatment with the 
brug. Digoxin also produced a modest but signiticant in- 
crease in left ventricular ejection fraction at rest. No differ- 
ence in survival was noted between placebo-treated and 
digoxin-treated patients in this study over the3 month period 
of observation. but the sNdy was neither large enough nor 
long enough to have the statistical paver needed to allow 
any definitive statement in this regard. 
Flye 1. Change in heart failure score WIF) when digoxin was 
substituted for placebo in 25 iodividwd patients with chronic heart 
failure plotted against the hean failure score of each patient doting 
the placebo phare tHF placebo,. Eleven putientr. designated by 
letters 0 lhrouah Y, failed to benefit from dipoxin thenov (and are 
shown on or b&w the d&ted line). where& the co&on of II 
patients improved uring the digoxin phase, Of the II nonrespoo- 
ders, 10 did not have ao audible third heart sound klmd circW 
during the placebo phase whereas patient P did have ao S, gallop 
~opncircla~. Seven nanresponders had a heart failure score ofwo 
duringtheplacebophpse. andhence could not have shown improve- 
ment; of these, patients 0. Q and W bad a normal let? ventricular 
ejection frwtion W.52) whereas patients X. Y and T had P serum 
digoxin level of only 0.5 o&l. Patients S. U and R also had a 
normal len ventricdar ejection fraction W.57). Only patient P with 
ischemic heart disease failed to show imorovement with diaoxin 
despite an adequate worn digorin level (1.8 n&d), adepra& left 
ventricular ejection fraction (0.13) and a heart lailure score of 5 
during the placebo phase. Redrawn with permikon from Lee et al. 
114). 
Digitalis or vasadiwors as first Iii agents. Despite nu- 
merous studies of the use of vascdilator drugs in patients 
with chmnic heart failure in recent years, we know little 
about the relative safety and etlicacy of these agents when 
compared with digitalis or about the combined use of digoxin 
and vasodilatws. Some impnrtanl clues. however. have 
emerged from a recent report by Ghcorghiade et al. (17). 
These investigators evaluated the effects of intravenous 
digoxin in II patients with severe heart failure whose con- 
dition was stabiliied with diuretics and vasodilators without 
treatment with digitalis. The addition of intravenous digoxin 
above the dashed zero line). Of the II uatients whose increased mean cardiac index by 30%. left ventricular stroke 
condition failed to improve, 7 had no sym&rts of heart 
failure (heart failure score = 0) during the placebo phase 
and. thus, could not (by definition) have shown any improve- 
ment during active treatment. Two patients had ischemic 
heat? disease with a normal left ventricular ejection fraction. 
and four had hypertrophic cardiomyopathy with a left ven- 
tricular ejection fraction ~0.52: these patients with pre- 
served systolic function would not have been expected to 
show improvement with digitalis. Of the 15 patients with 
systolic left ventricular dysfunction and symptoms of heart 
failure o” placebo, I4 showed a favorable response to 
long-term treatment with digoxin in the opinion of the 
blinded observers. Interestingly, each responder (and only 
one nonrespottdcr) had a third heart sound during placebo 
therapy, attesting to the presence of severe systolic dysfunc- 
tion in palients who responded favorably to digitalis. In 
contrast. in the placebo&mtmlled study if Flcg et al. (ISI. 
in which digitalis was not found to be clinically effective. the 
majority of enrolled patients were minimally symptomatic 
and only one patient had a third heart sound. 
work index by 62% and left ve&icular ejection fraction by 
38% (from 0.21 to 0.29) and decreased pulmonary capillary 
wedge pressure by 29%. Five of the II patients failed to 
respond to digoxin. and these patients had nearly nomtal 
hemodynamic measurements after optimal lherapy with di- 
uretics and vascdilaton. In contrast. the six patients who 
responded dramatically to digoxin had persistent hemody- 
namic evidence of left ventricular dysfunction despite ag- 
grcssive therapy with diuretics and vasodilaton. These 
observations are consistent with the view that patients with 
the most severe left ventriculur dysfunction show the most 
dramatic short-term response to digitalis. 
On/y one srrrdy kas direclly rompwed Ike long_rerm 
clinical eficls ofdigiralis and vnsodilorors in patients wirk 
chronic kenrl failwe. In this multicenter trial (IS). 3W 
patients treated with diuretics were randomly assigned to 
therapy with dig&n. captopril or placeboand were followed 
up ior 6 months. The study showed that both digitalis and 
captopril reduced the need for hospitalizations and emer- 
gency room visits for heart failure. Although exercise time 
and functional class were mure Bvorably affected by capto. 
pril than by dig&t, there was no significant difference 
between captopril- and digonin-treated patients with respect 
to any symptomatic end point. All of the patients in this 
study, however. had symptoms of hean failure mild enough 
to justify the withdrawal of cardiac glycosides; this entry 
requirement limits the scope of the conclusions that can be 
d&n from this study. Inaddition. the power of this study 
was not sufficiently large to allow any valid inferences to be 
drawn regarding possible differences in mortality among the 
three treatment groups. 
Considering the available data as discussed here and 
elsewhere (19). L would offer the following set of .+nswers to 
the question “should digoain be the drug of first choice after 
diuretics in the treatment of chronic congestive heart fail- 
UE?” 
1. Symptomatic patients with significant left ventricular 
systolic dysfunction and supraventricular tachy- 
arrhythmias (most often atrial fibrillation) and a rapid 
ventricular response. 
2. Symptomatic patients with substantially impaired left 
ventricular systolic function at high risk of developing 
clinically important hypotension on vasodilator Iher- 
aPY. 
3. Symptomatic patients with substantially impaired left 
ventricular systolic function at high risk of developing 
worsening renal failure an vasodilator therapy. 
I. Patients with symptoms of heart failure but with 
preserved left ventricular systolic function Iusually 
patients with diastolic dysfunction due to cardiac 
hypertrophy, myocardial ischemia or other causes of 
reduced ventricular compliance). 
2. Patients with mitral stenosis, normal sinus rhythm and 
no right ventricular failure. 
3. Patients with mild symptoms of heart failure (NYHA 
functional class II) who become asymptomatic and 
have well preserved exercise tolerance while receiving 
diuretics. 
UNCERTAIN, br Several Lrwge and I!~tporlwrt 
Ssbsct:: of Pruicnrs Including 
I. Severely svmplomaticpatients(NYHAclass IlIorlV) 
with left ventricular systolic dysfunction of such se- 
verity that both dig&n and vasodilators will probably 
he required (if tolerated) in addition to diuretics, 
Whereas no reliable data are available that can guide B 
2 
decision as to whether digaxin or vasadilators hould 
be added first to the diuretic retime”. individual 
clinical considerations will likely bc important; for 
example. marginal renal function. borderline systemic 
arterial pressure and marked sinus tachycardia t rest 
would favor the institution of digoxin therapy before 
the administration of vasodilators. 
Patients being treated with diuretics who have sinus 
rhythm with mild to modcrate symptoms due to im- 
paired left ventricular systolic function, preserved 
renal function and normal or mildly increased systemic 
arterial pressure. Most of these palienls will benefit 
from digoxin or vasodilators, and it is not clear which 
therapeutic intervention should be added first. Al- 
though both direct-acting vasodilators and converting 
enzyme inhibitors prolong life in certain patient sub- 
sets @l.2lL most patients enmlled in the survival 
trials conducted to date have had severe symptoms 
and all received background therapy with digilalis. 
I1 seem &or thor the avrrilahlv data ~dluw few weeping 
srneroliznlions regarding lhe relarise ,aer~*r of 3igoxin and 
vasodilarors in thew Irut two sabsen ofpodenrr. Tine time is 
long overdue for properly designed and stral.ified clinical 
trials to answer important, unresolved questions regarding 
the effects ofdigitalis glycosides on lhe quality oflife and the 
long-term outcome of patients with chronic heart failure. 
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Verne patients with chronic heart failure in the absence of 
atrial fibrillation. For a long time, the safety of digitalis was 
n source of concern. We now know that digitalis toxicity can 
be awide in most oatients with chronic heart failure and is 
not an important diwback to the use of this agent. These 
issues are no longer sources of controversy: in fact. there is 
little doubr that digitalis should be used in the treatment of 
chmnic heart failure. We do not know. however. when 
therapy with digitalis should be utilized. This new contrc- 
versy will likely continue for many years. as new phamxa- 
cologic interventions are developed and become accepted as 
effective therapeutic modalities and thus challen~c the 
choice of digitalis as a tint line agent after diuretics in the 
~reaunent of ratients with symptomatic left ventricular dys- 
function. 
How rhmrld we decide whelher digiro!is or 0 new *her”- 
perrric nppronch (such OS vasodiloror therapy) should be 
used a/.~ diuretics in chronic heart JX”re? We need to 
compare the effects ofthese two phamtacologic strategies on 
the three primary goals of treatment of these severely ill 
oatients: relief of sym~ltorns of hean failure. increase in 
exercise tolerance and &ongation of life. It is impartant o 
note that an increase in cardiac output or in left ventricular 
ejection fraction should not be considered to be one of the 
major goals of therapy in patients with symptomatic left 
ventricular dysfunction because changes in these variables 
do not parallel changes in symptoms or exercise capacity (Il. 
Which of the treatment options now available (digitalis or 
vascdilator drugs) provides the m”st consLstcnt benefits on 
symptotm and survival in patients with chmnic hean fail- 
ure? 
Effects of digitals and vasodiIators MI syt”pto”!S. Al- 
though digitalis can impmve left ventricular pafmmance in 
many patients with chmnic heart failure, the results of 
do”ble.blind, &&c-controllrd studies have raised cat- 
cents that thebe hemcdynamic effects may not be consis- 
tently translated inlo clinical benefits. Fleg et al. (2) noted 
that the withdrawal of digitalis from patients with chronic 
heart failure and normal sinus rhythm was accompanied by a 
small but significant increase in left ventricular end-diastolic 
dimension and circumferential shortening. but these adverse 
hemodvnamic chances were not accomwttied by any dete- 
rioratidn in sympt&ns or exercise ca&ty. The lack of 
clinical deterioration after the withdrawal of digitalis was 
The mle of digitalis in the management of congestive heati 
failure has been the center of controversy for m”re than 200 
years. but the focus of thin debate has changed substantially 
during the wurse ofclinical investigations with the drug. For 
a long time, the efficacy of digitalis in the treatment of 
congestive heart failure in patients with nomxal sinus rhythm 
was in doubt. We n”w know that digitalis can be effective in tricular ejection fraction at peak exercise, but these hem”- 
contimted in another double-blind, placebo-cordmlled trial 
by Gheorghiade t al. (3). who noted no significant changes 
in symptoms. ien ventricular ejection fraction or exercise 
duration in patients with chmnic heart failure in whom 
digitalis was withdrawn for I month. In a third. recently 
completed. double-blind crossover sludy of digoxin in pa- 
tients with chronic heart failure due to ischemic hearI 
disease, Fleg et al. (4) found that digitalis pmdtlced a 
significant increase in systolic blood pressure and lefl ven- 
